Thermo Fisher Scientific Acquires Affinity BioReagents
News Jul 18, 2008
Thermo Fisher Scientific Inc. has announced that it has acquired Affinity BioReagents, a provider of antibodies, peptides, proteins and other reagents for life science research, based in Golden, Colorado.
“Affinity BioReagents is an ideal complement to our existing capabilities in protein research,” said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific.
“This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications.” Such applications include Western blotting, ELISA, immunohistochemistry, flow cytometry and mass spectroscopy.
Affinity BioReagents has an offering of more than 35,000 reagents – primarily monoclonal and polyclonal antibodies – which are used in numerous fields of medical and academic research, as well as drug discovery.
The company also provides recombinant proteins and custom antibody-production services. Affinity BioReagents had annual revenues of approximately $6 million in 2007, and will be integrated into Thermo Fisher’s Analytical Technologies Segment.